ROPHAI

• The Labor Crisis: Hospital and donation center nursing/phlebotomist turnover exceeds 25% annually, escalating structural staffing costs.
• Workflow Inefficiency: Up to 30% of difficult venous access (DVA) patients require multiple painful needle sticks, causing substantial clinical delays.
• Competitor Failure Modes: Heavily funded competitors have raised $70M–$90M+ but remain commercially bottlenecked. They build either massive, immobile 300+ lb stationary kiosks restricted to high-volume outpatient hubs, or low-automation handheld tools that fail to eliminate manual clinical error.

[COMPETITORS: Fixed Kiosks OR Handhelds] ──> Restricted to Centralized Hubs (Low TAM)
[OUR PLATFORM: Mobile Bedside + HITL]    ──> Penetrates All 4 Core Segments (Max TAM)

1. Plasma Donation Centers: High-volume automated throughput to secure early recurring cash flow. 
2. Blood Donation Networks: Scalable operational support to lower onsite clinical footprints.
3. Commercial IVD Laboratories: High-speed automation designed for centralized hubs like Quest Diagnostics and Labcorp.
4. Inpatient Hospital Wards & PCP Clinics: Bedside mobility optimized for tight clinical environments, emergency rooms, and intensive care units.

[Traditional Manual Model] ──> 4 Beds Require 4 Full-Time Phlebotomists ($200,000/yr labor)
[Our RaaS HITL Model]      ──> 4 Beds Require 1 Full-Time Operator      ($50,000/yr labor)
──────────────────────────────────────────────────────────────────────────────────────────
NET ANNUAL SITE LABOR SAVINGS:                                           $150,000 / year

• The Headcount Multiplier: One technician manages 3 to 4 automated robotic beds simultaneously from a central station. The AI handles tracking and needle deployment; the human operator merely provides quick visual confirmation and physical override control.

• Foundational Layer: Exclusive, global commercial license to 4 university patents (21 claims) developed over 5 years via $5M in initial research, protecting automated needle-insertion mechanics.
• Commercial Layer: 27 proprietary claims applied for by our spin-off team, protecting our mobile cart locks, multi-spectral AI imaging alignment systems, and HITL safety overrides.
• The AI Data Moat: 100% ownership of a proprietary dataset spanning 1,000+ clinical draw hours, creating a machine learning barrier that competitors cannot easily copy.

• FDA Alignment: Completed pre-submission meetings with the FDA, securing explicit structural alignment on our De Novo clinical protocol.
• Proven Human Testing: The core mechanics have already been successfully validated on hundreds of human donors across 15 early studies (customer, user, donor, patient, HCP inputs and human factor studies)
• Clear Launch Horizon: Alpha designs are frozen, Beta units are built, and our Series A capital maps to a definitive 1-year pivotal trial submission and a 2.5-year maximum window to commercial launch.

• Upfront Integration Fee: $XX per machine (Includes setup, network linking, and operator training).
• Predictable Support Fee (ARR): $XX per year ($XX/month) for software updates and SLA tier access.
• The Tiered Pay-Per-Use Scaling Engine: upto $XX monthly minimum floor ($XX baseline annual click revenue).

• 80+% Blended Net Profit Margin

• Chief Executive Officer (CEO): 25 Years senior MedTech commercialization and executive leadership experience.
• Chief Operating/Financial Officer (COO/CFO): 20 Years managing financial structures across cross-functional Pharma and MedTech environments.
• Chief Technology Officer (CTO): 12 Years designing and deploying complex robotic medical devices.